Literature DB >> 26136587

PNPLA3 I148M Variant Influences Circulating Retinol in Adults with Nonalcoholic Fatty Liver Disease or Obesity.

Alison Mondul1, Rosellina M Mancina2, Andrea Merlo3, Paola Dongiovanni3, Raffaela Rametta3, Tiziana Montalcini4, Luca Valenti3, Demetrius Albanes1, Stefano Romeo5.   

Abstract

BACKGROUND: Retinol is a lipid-soluble essential nutrient that is stored as retinyl esters in lipid droplets of hepatic stellate cells. Patatin-like phospholipase domain-containing 3 (PNPLA3), through its retinyl-palmitate lipase activity, releases retinol from lipid droplets in hepatic stellate cells in vitro and ex vivo. We have shown that the genetic variant I148M (rs738409) reduces the PNPLA3 retinyl-palmitate lipase activity.
OBJECTIVE: The aim of the present genetic association study was to test whether overweight/obese carriers of the PNPLA3 148M mutant allele had lower circulating concentrations of retinol than individuals who are homozygous for the 148I allele.
METHODS: PNPLA3 I148M (rs738409) was genotyped by Taqman assay in 76 overweight/obese individuals [BMI (kg/m(2)) ≥25; mean ± SD age: 59.7 ± 11.4 y; male gender: 70%] with a histologic diagnosis of nonalcoholic fatty liver disease (NAFLD; namely the Milan NAFLD cohort) and in 413 obese men (BMI ≥30; mean ± SD age: 57.1 ± 4.9 y) from the α-Tocopherol, β-Carotene Cancer Prevention (ATBC) Study. Serum concentrations of retinol and α-tocopherol were measured by HPLC in both cohorts. β-Carotene concentrations in the ATBC study were measured by using HPLC.
RESULTS: The PNPLA3 148M mutant allele was associated with lower fasting circulating concentrations of retinol (β = -0.289, P = 0.03) in adults with NAFLD (Milan NAFLD cohort). The PNPLA3 148M mutant allele was also associated with lower fasting circulating concentrations of retinol in adults with a BMI ≥30 (ATBC study; β = -0.043, P = 0.04).
CONCLUSION: We showed for the first time, to our knowledge, that carriers of the PNPLA3 148M allele with either fatty liver plus obesity or obesity alone have lower fasting circulating retinol concentrations.
© 2015 American Society for Nutrition.

Entities:  

Keywords:  NAFLD; PNPLA3; RBP4; obesity; retinol

Mesh:

Substances:

Year:  2015        PMID: 26136587      PMCID: PMC4516767          DOI: 10.3945/jn.115.210633

Source DB:  PubMed          Journal:  J Nutr        ISSN: 0022-3166            Impact factor:   4.798


  27 in total

Review 1.  Retinol-binding protein: the serum transport protein for vitamin A.

Authors:  W S Blaner
Journal:  Endocr Rev       Date:  1989-08       Impact factor: 19.871

2.  Effects of acute inflammation on plasma retinol, retinol-binding protein, and its mRNA in the liver and kidneys of vitamin A-sufficient rats.

Authors:  F J Rosales; S J Ritter; R Zolfaghari; J E Smith; A C Ross
Journal:  J Lipid Res       Date:  1996-05       Impact factor: 5.922

3.  Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma.

Authors:  Y-L Liu; G L Patman; J B S Leathart; A-C Piguet; A D Burt; J-F Dufour; C P Day; A K Daly; H L Reeves; Q M Anstee
Journal:  J Hepatol       Date:  2014-03-06       Impact factor: 25.083

4.  Serum vitamin A, retinol-binding protein, and prealbumin concentrations in protein-calorie malnutrition. II. Treatment including supplemental vitamin A.

Authors:  F R Smith; D S Goodman; G Arroyave; F Viteri
Journal:  Am J Clin Nutr       Date:  1973-09       Impact factor: 7.045

5.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease.

Authors:  David E Kleiner; Elizabeth M Brunt; Mark Van Natta; Cynthia Behling; Melissa J Contos; Oscar W Cummings; Linda D Ferrell; Yao-Chang Liu; Michael S Torbenson; Aynur Unalp-Arida; Matthew Yeh; Arthur J McCullough; Arun J Sanyal
Journal:  Hepatology       Date:  2005-06       Impact factor: 17.425

6.  The alpha-tocopherol, beta-carotene lung cancer prevention study: design, methods, participant characteristics, and compliance. The ATBC Cancer Prevention Study Group.

Authors: 
Journal:  Ann Epidemiol       Date:  1994-01       Impact factor: 3.797

7.  Recombinant PNPLA3 protein shows triglyceride hydrolase activity and its I148M mutation results in loss of function.

Authors:  Piero Pingitore; Carlo Pirazzi; Rosellina M Mancina; Benedetta M Motta; Cesare Indiveri; Arturo Pujia; Tiziana Montalcini; Kristina Hedfalk; Stefano Romeo
Journal:  Biochim Biophys Acta       Date:  2013-12-22

Review 8.  PNPLA3 I148M polymorphism and progressive liver disease.

Authors:  Paola Dongiovanni; Benedetta Donati; Roberta Fares; Rosa Lombardi; Rosellina Margherita Mancina; Stefano Romeo; Luca Valenti
Journal:  World J Gastroenterol       Date:  2013-11-07       Impact factor: 5.742

9.  Expression and characterization of a PNPLA3 protein isoform (I148M) associated with nonalcoholic fatty liver disease.

Authors:  Yongcheng Huang; Jonathan C Cohen; Helen H Hobbs
Journal:  J Biol Chem       Date:  2011-08-30       Impact factor: 5.157

10.  The PNPLA3 Ile148Met interacts with overweight and dietary intakes on fasting triglyceride levels.

Authors:  Ivana A Stojkovic; Ulrika Ericson; Gull Rukh; Martin Riddestråle; Stefano Romeo; Marju Orho-Melander
Journal:  Genes Nutr       Date:  2014-02-22       Impact factor: 5.523

View more
  46 in total

Review 1.  Genetically modified mouse models to study hepatic neutral lipid mobilization.

Authors:  Guenter Haemmerle; Achim Lass
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-06-05       Impact factor: 5.187

2.  The PNPLA3 I148M variant is associated with transaminase elevations in type 2 diabetes patients treated with basal insulin peglispro.

Authors:  S Pillai; S Duvvuru; P Bhatnagar; W Foster; M Farmen; S Shankar; C Harris; E Bastyr; B Hoogwerf; A Haupt
Journal:  Pharmacogenomics J       Date:  2017-11-21       Impact factor: 3.550

3.  17-Beta Hydroxysteroid Dehydrogenase 13 Is a Hepatic Retinol Dehydrogenase Associated With Histological Features of Nonalcoholic Fatty Liver Disease.

Authors:  Yanling Ma; Olga V Belyaeva; Philip M Brown; Koji Fujita; Katherine Valles; Suman Karki; Ynto S de Boer; Christopher Koh; Yanhua Chen; Xiaomeng Du; Samuel K Handelman; Vincent Chen; Elizabeth K Speliotes; Cara Nestlerode; Emmanuel Thomas; David E Kleiner; Joseph M Zmuda; Arun J Sanyal; Natalia Y Kedishvili; T Jake Liang; Yaron Rotman
Journal:  Hepatology       Date:  2019-03-05       Impact factor: 17.425

Review 4.  Mechanisms of liver fibrosis and its role in liver cancer.

Authors:  Debanjan Dhar; Jacopo Baglieri; Tatiana Kisseleva; David A Brenner
Journal:  Exp Biol Med (Maywood)       Date:  2020-01-10

5.  Unexpected metabolic disorders induced by endocrine disruptors in Xenopus tropicalis provide new lead for understanding amphibian decline.

Authors:  Christophe Regnault; Marie Usal; Sylvie Veyrenc; Karine Couturier; Cécile Batandier; Anne-Laure Bulteau; David Lejon; Alexandre Sapin; Bruno Combourieu; Maud Chetiveaux; Cédric Le May; Thomas Lafond; Muriel Raveton; Stéphane Reynaud
Journal:  Proc Natl Acad Sci U S A       Date:  2018-04-23       Impact factor: 11.205

6.  The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent.

Authors:  Rosellina Margherita Mancina; Paola Dongiovanni; Salvatore Petta; Piero Pingitore; Marica Meroni; Raffaela Rametta; Jan Borén; Tiziana Montalcini; Arturo Pujia; Olov Wiklund; George Hindy; Rocco Spagnuolo; Benedetta Maria Motta; Rosaria Maria Pipitone; Antonio Craxì; Silvia Fargion; Valerio Nobili; Pirjo Käkelä; Vesa Kärjä; Ville Männistö; Jussi Pihlajamäki; Dermot F Reilly; Jose Castro-Perez; Julia Kozlitina; Luca Valenti; Stefano Romeo
Journal:  Gastroenterology       Date:  2016-02-02       Impact factor: 22.682

Review 7.  Vitamin A signaling and homeostasis in obesity, diabetes, and metabolic disorders.

Authors:  William S Blaner
Journal:  Pharmacol Ther       Date:  2019-01-29       Impact factor: 12.310

Review 8.  Genetic Pathways in Nonalcoholic Fatty Liver Disease: Insights From Systems Biology.

Authors:  Silvia Sookoian; Carlos J Pirola; Luca Valenti; Nicholas O Davidson
Journal:  Hepatology       Date:  2020-07       Impact factor: 17.425

Review 9.  NAFLD in children: new genes, new diagnostic modalities and new drugs.

Authors:  Valerio Nobili; Anna Alisi; Luca Valenti; Luca Miele; Ariel E Feldstein; Naim Alkhouri
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-07-05       Impact factor: 46.802

Review 10.  Nutrigenomics and Nutrigenetics in Metabolic- (Dysfunction) Associated Fatty Liver Disease: Novel Insights and Future Perspectives.

Authors:  Marcello Dallio; Mario Romeo; Antonietta Gerarda Gravina; Mario Masarone; Tiziana Larussa; Ludovico Abenavoli; Marcello Persico; Carmelina Loguercio; Alessandro Federico
Journal:  Nutrients       Date:  2021-05-15       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.